M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Phase 2

Completed

Conditions: Chronic Myeloid Leukemia
Minimal Residual Disease

Interventions: Biological: Synthetic Tumor-Specific Breakpoint Peptide Vaccine

First Posted Date: 2005-12-20

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT00267085

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Evaluate PKs and Efficacy Assessment of Palifermin in Patients With Sarcoma

Phase 2

Completed

Conditions: Sarcoma
Oral Mucositis

Interventions: Drug: Placebo
Drug: Palifermin
Drug: Adriamycin (Doxorubicin)
Drug: Ifosfamide
Drug: Vincristine
Drug: Cisplatin

First Posted Date: 2005-12-20

Last Posted Date: 2012-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 49

Registration Number: NCT00267046

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

Phase 2

Completed

Conditions: Acute Myeloid Leukemia
Mastocytosis
Myelodysplastic Syndromes
Agnogenic Myeloid Metaplasia
Myelofibrosis
Polycythemia Vera
Hypereosinophilic Syndrome
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Dasatinib (BMS-354825)

First Posted Date: 2005-11-18

Last Posted Date: 2023-12-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 68

Registration Number: NCT00255346

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

Interventions: Drug: Dasatinib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2005-11-16

Last Posted Date: 2024-06-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 156

Registration Number: NCT00254423

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Phase 1

Completed

Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7
Recurrent Lung Non-Small Cell Carcinoma
Stage IA Lung Non-Small Cell Carcinoma AJCC v7
Stage IIA Lung Non-Small Cell Carcinoma AJCC v7
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: Erlotinib
Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis

First Posted Date: 2005-11-16

Last Posted Date: 2024-07-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00254384

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Melanoma Vaccine With Peptides and Leuprolide

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Leuprolide
Biological: MAGE-3 Peptide

First Posted Date: 2005-11-16

Last Posted Date: 2019-10-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 98

Registration Number: NCT00254397

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

Phase 3

Terminated

Conditions: Gastrointestinal Cancer
Rectal Cancer

Interventions: Drug: Procrit (epoetin alfa)

First Posted Date: 2005-11-16

Last Posted Date: 2018-10-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00254436

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: Mitoxantrone
Drug: Rituximab
Drug: Filgrastim

First Posted Date: 2005-11-16

Last Posted Date: 2019-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00254410

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Drug: Docetaxel
Drug: RAD001
Drug: Dexamethasone

First Posted Date: 2005-11-15

Last Posted Date: 2023-10-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00253318

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery

Phase 2

Completed

Conditions: Hepatocellular Carcinoma
Liver Cancer

Interventions: Drug: Bevacizumab (Avastin)
Drug: Erlotinib

First Posted Date: 2005-10-20

Last Posted Date: 2013-05-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT00242502

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy